¿Sabía que la Parkinson’s Foundation está llevando a cabo un estudio genético actualmente, llamado PD GENEration: Impulsado por la Parkinson’s Foundation? Aprenda más acerca de este innovador estudio y cómo ayuda a las personas con la enfermedad de Parkinson (EP).

Acompañe al neurogenetista Dr. Ignacio Mata, de la Cleveland Clinic, un Centro de Excelencia de la Parkinson's Foundation, mientras destaca el papel de la genética en la investigación de la EP, la importancia de la diversidad en la investigación y cómo pueden ayudar los participantes a mejorar nuestra comprensión de la EP y acelerar el desarrollo de mejores alternativas de tratamiento.

¿Qué es PD GENEration?

PD GENEration es una iniciativa global de investigación de la Parkinson’s Foundation que ofrece pruebas genéticas para los genes relacionados con el Parkinson y la consejería genética sin costo para las personas con la enfermedad de Parkinson, en español e inglés.

¿Por qué participar?

Las pruebas genéticas pueden ser una poderosa herramienta para descubrir las vías biológicas que causan el Parkinson y este entendimiento puede conducir a mejores tratamientos y cuidados para todas las personas con Parkinson.

Al participar en el estudio, los participantes pueden descubrir nuevos conocimientos acerca de su genética, entender los riesgos de su familia y ayudar a beneficiar a las futuras generaciones.

Aprenda más e inscríbase ahora.

For the first time, the Parkinson’s Foundation is connecting its mission and vision to policy and advocacy work that drives change at the federal and state levels. Through this work, the Foundation aims to shape a future where Parkinson’s disease (PD) research is steadily funded, every person with PD has access to the care and support they deserve, and fewer people develop PD in the first place.

Leading these efforts is Andi Lipstein Fristedt, Executive Vice President, Chief Strategy and Policy Officer. Andi leads the Foundation’s strategic direction and policy initiatives. Andi brings nearly 20 years of leadership experience to the Parkinson’s Foundation. In this interview, Andi shares how she views policy as an opportunity and powerful tool to accelerate progress and create meaningful change — starting now.

1. Can you tell us about your prior policy experience in the health space?

Before joining the Parkinson's Foundation, I spent most of my career in government. Most recently, I served as Deputy Director at the Centers for Disease Control (CDC) where I led the agency’s global health work, as well as its cross cutting offices related to policy, budget, communications and congressional engagement. Before that I was at the Food and Drug Administration (FDA) as Deputy Commissioner for Policy, Legislation & International Affairs where I advanced key policies to strengthen the agency’s regulatory agenda. I previously served on Capitol Hill for almost a decade with the Senate Committee on Health, Education, Labor and Pensions and as Chief of Staff in the Oregon State Legislature.

These diverse experiences fuel my passion to bridge the gap between Parkinson’s research, care and policy at both the state and federal level.

2. Why bring your talents to the Parkinson’s community?

Like so many others, Parkinson’s disease has impacted people I care deeply about. I am excited about the opportunity to come to an organization that understands the people it serves, centers them in the work, and is positioned to drive progress alongside them. I’m here to lead change for people living with Parkinson’s and their care partners. These are challenging times in public policy, but there's a real opportunity to reimagine what’s possible. The federal and state policy landscape gives us opportunity to make short- and long-term changes to strengthen public health and health care for years to come.

3. What are the top policy issues for people with Parkinson’s? How is the Parkinson’s Foundation addressing them?

Right now, the Foundation is advancing a number of policy priorities:

• Protecting and advancing the National Parkinson's Project. The National Plan to End Parkinson’s Act was signed into law in 2024, creating the National Parkinson’s Project, and now we’re working to push the administration to implement it in a timely manner. This is the first federal project dedicated to PD research, prevention and care — our policy work will help ensure it delivers real results for people with PD.
• Research funding. Parkinson's is the fastest-growing neurodegenerative disease, yet federal funding has not kept pace with its rise. In addition to advocating for more funding at the National Institutes of Health (NIH) and other federal agencies, we're starting to see research funding opportunities in state governments. Our goal is to secure $600 million a year for Parkinson's research at the NIH by 2028. We aim to fully deliver on the promise of this pivotal moment in PD discovery.

“Our goal is to secure $600 million a year of Parkinson's disease research at the NIH by 2028. We aim to fully deliver on the promise of this pivotal moment in PD discovery.”

• Environmental health threats. Environmental factors, such as chemicals like paraquat and trichloroethylene (TCE) have been tied to Parkinson's, and this is where policy changes can make a big difference. Paraquat is banned in more than 70 countries, including China, even though they still sell it to the U.S. It's something that we have the power to change by working with the Environmental Protection Agency (EPA) and engaging with state governments.
• Helping people access PD care. There's so much work to do here at the federal and state levels, making sure that we're supporting policies that help people with Parkinson’s access timely, quality and affordable care wherever they live. For example, we’ve seen how hard the uncertainty around telehealth coverage has made care for providers and people with PD.
• Supporting public health agencies. Public health agencies need the tools and the authority to advance prevention and support new PD treatments and care breakthroughs. This is not a given. We work to ensure the strongest possible public health programs, to ensure that we're moving towards better treatments and a cure for Parkinson's.

4. How can people with Parkinson’s and allies get involved?

There are a lot of opportunities for people with Parkinson's and the people who care about them to engage in policy. Policymakers need to hear your stories and experiences as they are considering policy changes, and we’re working to help people engage with policymakers, year-round.

One exciting opportunity to engage with Congress is coming up March 15 to 18, in Washington, D.C., through our Parkinson's Policy Forum and Day of Action. We will host this event alongside The Michael J. Fox Foundation for Parkinson’s Research and the American Parkinson Disease Association. We’ll be inviting advocates to come to D.C., spend time together as a community and engage lawmakers around key priorities for the Parkinson's community.

But you don’t have to be in Washington, D.C. or a state capital to reach out to your lawmakers, and there are lots of other ways to be involved in advocacy. The Parkinson’s Foundation is building and expanding our platform to share timely action items and help support advocates who want to do that work and make their voices heard.

5. Why should policymakers care about policies that impact Parkinson’s?

Parkinson’s is the fastest-growing neurodegenerative disease, with more than 1 million Americans living with PD and 90,000 new people diagnosed each year. Policymakers have a responsibility to address diseases like PD that impact communities and drive up health care costs. Research for cures has always been, and must remain, bipartisan. When policymakers hear stories from their constituents facing life-altering issues, they listen — especially when those voices unite.

We are at a pivotal moment, with scientific advancements within reach. Now is not the time to pump the breaks — but hit the gas to take advantage of the incredible scientific progress that has been happening to yield real changes for people living with PD. Sustained congressional investment in research and programs leads directly to earlier detection, better treatments, and a cure. And today, we know policy actions by state and federal agencies can protect people from developing PD in the first place.

6. What should people in the PD community tell their Congressperson or State Representative?

Part of the Parkinson’s Foundation policy strategy is showing how policy decisions shape the daily lives of people with Parkinson's and, in turn, ensuring that policy changes reflect lived experience. We need legislators to see a future where new disease-modifying therapies exist, where there are enough specialists to treat people with Parkinson’s, where people are protected from toxic chemicals that contribute to the development of PD and where there's a cure. People with Parkinson’s and their families play a critical role in sharing what these possibilities mean to them.

Lawmakers respond to personal stories — they make this disease tangible. Connecting policy to the realities of living with Parkinson’s is a vital component of our policy work.

7. What gives you hope about helping people with Parkinson’s advocate for policy change?

The community. There are so many people across the country and world, demanding a different future where we think more about Parkinson's disease on a federal and state policy level. The strength and passion of this community is what will ultimately make the difference in the policy space.

8. What’s next for Parkinson’s Foundation policy and advocacy work?

At the Parkinson’s Foundation, we’re focused on policies that improve life for people living with PD today and accelerate progress toward better care and a cure. There's so much change happening across health agencies, and we know that a strong, effective policy strategy will help advance care, research and support for people with Parkinson's.

We’re excited for the Parkinson's Policy Forum and Day of Action coming up in March and the launch of our policy priorities.

We also invite our community to help raise PD awareness. Join us at the local level, stay connected with us and share information with friends and family.

Make your voice heard. Sign up today to receive our emails and take part in Parkinson’s Foundation advocacy work. If you already receive our emails, sign in to the Online Supporter Center and opt into Policy emails under Communication Preferences.

Sleep problems are a common non-movement symptom for people who live with Parkinson’s disease (PD). However, a new large-scale study reveals that untreated obstructive sleep apnea (OSA) may actually increase the risk of developing Parkinson’s disease in the first place, but treating it with continuous positive airway pressure (CPAP) may help reduce that risk.

Obstructive sleep apnea is a condition where breathing repeatedly stops and starts during sleep due to a blocked or narrowed airway. This prevents the body from getting enough oxygen, disrupting sleep quality and putting stress on various organs, including the brain. An estimated 30 million Americans have OSA, though many remain undiagnosed.

Study Results

The study, published in JAMA Neurology, and led by researchers at Oregon Health & Science University and the Portland VA Health Care System analyzed electronic health records from veterans who received care through the Department of Veterans Affairs between 1999 and 2022.

Of the more than 11 million veterans included in the analysis, about 1.5 million (13.7%) had OSA. After adjusting for factors like age, obesity and cardiovascular conditions, the researchers found a strong link between untreated sleep apnea and Parkinson’s disease. Veterans with OSA showed 1.61 additional cases of Parkinson’s per 1,000 people at six years from OSA diagnosis compared to those without the condition. Compared to those without the condition, veterans with OSA were nearly twice as likely to develop Parkinson’s. The link between OSA and Parkinson’s was even more pronounced in female veterans.

OSA can be effectively treated using CPAP machines. Importantly, the study found that early CPAP treatment reduced the risk of developing Parkinson’s. Veterans who began CPAP use within two years of their diagnoses were about 30% less likely to develop Parkinson’s compared to those who didn’t use CPAP.

In addition, for those who did eventually get diagnosed with Parkinson’s, the study showed that using CPAP early after an OSA diagnosis was associated with a reduction in the rates of falls, fractures and mortality.

Highlights

• The study analyzed health records of more than 11 million U.S. veterans over a 23-year period.
• People with untreated obstructed sleep apnea had nearly twice the risk of developing Parkinson's disease compared to those without OSA.
• The link between OSA and Parkinson's risk was even stronger in female veterans.
• Early CPAP treatment in those with OSA significantly reduced the number of Parkinson's cases.
• For those who developed Parkinson’s, early CPAP use was linked to reduced risk of falls, fractures, and mortality.

What Does This Mean?

This research suggests that obstructive sleep apnea may be a modifiable risk factor for Parkinson’s disease — meaning it can potentially be treated. It is important to note that the results of this study are correlations; the study did not prove that sleep apnea causes Parkinson’s, or that CPAP can prevent the development of Parkinson’s. However, the links between OSA, CPAP use, and Parkinson’s highlight the importance of diagnosing and managing sleep disorders early.

Additionally, these results support similar findings from the dementia field, in which a study found that CPAP treatment of OSA was associated with reduced odds of developing dementia.

OSA is extremely common and underdiagnosed. The Global Burden of Obstructive Sleep Apnea study found OSA to be a widespread concern “estimated to affect nearly 936 million adults aged between 30 and 69 worldwide.” Because of how widespread OSA is, linking it to Parkinson’s means there is a large opportunity to reduce risk and improve outcomes through better detection and treatment.

What Do These Findings Mean for People with Parkinson’s Right Now?

While this research does not change day-to-day treatment for people already living with Parkinson’s, it reinforces the importance of addressing sleep problems, which are already common in Parkinson’s.

Poor sleep can worsen movement and non-movement symptoms, affect quality of life and impact overall health. Research continues to link sleep apnea with negative health outcomes. If you experience symptoms of sleep apnea, such as loud snoring, gasping during sleep or excessive daytime fatigue, talk to your doctor. A sleep study can determine if you have OSA, and treatments like CPAP can help improve your sleep quality and potentially support your overall health.

Learn More

The Parkinson’s Foundation believes in empowering the Parkinson’s community through education. Learn more about PD and sleep through our resources below, or by calling our free Helpline at 1-800-4PD-INFO (1-800-473-4636) for answers to your Parkinson’s questions.

• Sleep Problems in Parkinson’s
• Veterans & Parkinson's
• Podcast: Parkinson's Disease and Sleep
• Dopamine Medication May Help with Sleep, Depression and Pain
• Meet a Researcher Exploring Parkinson’s-related Sleep Disruption